Evidence map›Paper›PMID 27984110›Full record

ArticleThe Journal of urology2017

More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades.

J B Eifler, J Alvarez, T Koyama, R M Conwill, C R Ritch, K E Hoffman, M J Resnick, D F Penson, D A Barocas, Collaborators

Abstract read
In one paragraph

Article in The Journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

J B EiflerDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
J AlvarezDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
T KoyamaDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
R M ConwillDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
C R RitchDepartment of Urology, University of Miami Health System, Miami, Florida.
K E HoffmanDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
M J ResnickDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
D F PensonDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
D A BarocasDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: Dan.barocas@vanderbilt.edu.
Collaborators
Vanderbilt University Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Miami Health System · US

Funding

Comparative Effectiveness of Treatments for Localized Prostate CancerR01HS019356 · AHRQ · VANDERBILT UNIVERSITY · PI PENSON, DAVID F. · 2010 to 2010
$7.6M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067009 · PC · FRED HUTCHINSON CANCER RESEARCH CENTER · PI THOMAS, DAVID B · 1996 to 2000
$3.0M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067010 · PC · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROSS, RONALD K · 1996 to 2000
$2.4M
Comparative Effectiveness of Modern Therapies for Localized Prostate CancerR01HS022640 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PENSON, DAVID F. · 2013 to 2013
$1.8M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067006 · PC · EMORY UNIVERSITY · PI YOUNG, JOHN L · 1996 to 2000
$1.7M
Race, Comorbidity & Long Term Prostate Cancer OutcomesR01CA114524 · NCI · VANDERBILT UNIVERSITY · PI PENSON, DAVID F. · 2007 to 2009
$1.7M
Trends in Surveillance for Localized Prostate Cancer and Barriers to its UseR03CA173812 · NCI · VANDERBILT UNIVERSITY · PI BAROCAS, DANIEL A · 2013 to 2014
$154k
AHRQ HHS R01 HS019356AHRQ HHS R01 HS022640NCI NIH HHS N01 PC067006NCI NIH HHS N01 PC067009NCI NIH HHS N01 PC067010NCI NIH HHS R01 CA114524NCI NIH HHS R03 CA173812
6 · The paper itself

Abstract

purposeUrologists have been criticized for overtreating men with low risk prostate cancer and for passively observing older men with higher risk disease. Proponents of active surveillance for low risk disease and critics of watchful waiting for higher risk disease have advocated for more judicious use of observation. Thus, we compared 2 population based cohorts to determine how expectant management has evolved during the last 2 decades. MATERIALS AND

methodsA total of 5,871 men with localized prostate cancer were enrolled in the PCOS (Prostate Cancer Outcomes Study) or the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study. We compared the use of definitive treatment vs expectant management (watchful waiting or active surveillance) across cohorts, focusing on the influence of disease risk, age and comorbidities.

resultsUse of watchful waiting or active surveillance was similar in PCOS and CEASAR (14% in each). Compared to the PCOS, more men in the CEASAR study with low risk disease selected watchful waiting or active surveillance (25% vs 15%, respectively), whereas fewer men with intermediate (7% vs 14%) and high risk (3% vs 10%) disease chose watchful waiting or active surveillance (p <0.001 for each). The association of disease risk with watchful waiting or active surveillance was significantly larger in CEASAR than in PCOS (OR 7.3, 95% CI 3.4 to 15.7). Older age was associated with watchful waiting or active surveillance in both cohorts but there was no association between comorbidity and watchful waiting or active surveillance in the CEASAR study.

conclusionsUse of watchful waiting or active surveillance was more aligned with disease risk in CEASAR compared to PCOS, suggesting there has been a pivot from watchful waiting to active surveillance. While older men were more likely to be observed, comorbidity had little, if any, influence.

Indexed as

Watchful WaitingAdultAgedCohort StudiesHumansMaleMiddle AgedPatient SelectionProstate-Specific AntigenProstatic NeoplasmsRiskProstate-Specific Antigenantineoplastic protocolsprostatic neoplasmsrisk assessmentwatchful waiting

Identifiers

PMID27984110
PMCPMC5315642
OpenAlexW2544905964

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.